COMP <GO>
TXG vs JNJ // FORWARD P/E MULTIPLE
10x Genomics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TXG 3
— JNJ 9
▲ FORWARD P/E MULTIPLE LEADER: JNJ
LAST: $70.11 (-14.03%) • MKT CAP: $10.63B
forward-pe
24.0x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 67.90% | +1.20 | TXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | 25.50% | -31.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 2.97% | -1.75 | JNJ | /fcf-yield <GO> |
| Operating Margin | -9.50% | 34.70% | -44.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -6.80% | 28.50% | -35.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 6.00% | -0.80 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 5.59 | +19.43 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.20% | +0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 60.4 | -15.86 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 24.0x | 23.0x | +1.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.63B | $662.49B | -$651.87B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | JNJ REV | TXG GROSS % | JNJ GROSS % | TXG FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $94.19B | 69.1% | 67.9% | $130.1M | $19.70B |
| FY 2024 | $610.8M | $88.82B | 67.9% | 69.1% | -$5.7M | $19.84B |
| FY 2023 | $618.7M | $85.16B | 44.0% | 44.0% | -$43.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
JNJ // BETA 1.08